Manuel RUIZ will succeed Stephane MASCARAU as General Manager of Sveja China, with an appointment effective 1 October 2022

Recently, Svea's official WeChat released a message that Stephane MASCARAU, general manager of Sveia China, will be promoted to the regional head of Sveia Group, responsible for the Greater China region (including the mainland, Hong Kong, Macau and Taiwan) and the Australian market

Recently, Svea's official WeChat released a message that Stephane MASCARAU, general manager of Sveia China, will be promoted to the regional head of Sveia Group, responsible for the Greater China region (including the mainland, Hong Kong, Macau and Taiwan) and the Australian market

At the same time, Manuel RUIZ will succeed Stephane MASCARAU as General Manager of Sveia China, responsible for Chinese mainland and the Hong Kong market, reporting

The new appointments will take effect on

According to Svea, since 2017, under the leadership of Stephane, Svea China has continuously expanded the construction of channels and continued to promote the accessibility of

According to Svea, since 2017, under the leadership of Stephane, Svea China has continuously expanded the construction of channels and continued to promote the accessibility of

The new General Manager, Manuel RUIZ, has more than 20 years of senior experience

The new General Manager, Manuel RUIZ, has more than 20 years of senior experience

Shift from chronic diseases to the field of tumors

From chronic diseases to tumors From chronic diseases to tumors from chronic diseases to tumors

In the eyes of the outside world, Svea, as the second largest pharmaceutical company in France, has always been somewhat low-key and special

In the eyes of the outside world, Svea, as the second largest pharmaceutical company in France, has always been somewhat low-key and special

According to Sveia China's official website, Sveia has a total of 21,800 employees worldwide, and the company invests an average of 20% of its branded drug revenue in drug research and development every year

As a "leader" in the field of chronic diseases, Svea began to set foot in the field of

As a "leader" in the field of chronic diseases, Svea began to set foot in the field of
oncology in 2015.
In 2018, Sveia acquired the Shire Oncology business unit for $2.
4 billion, which officially marked the beginning of Svea's full-scale entry into the oncology business, which also entered the US market
.
In 2020, Svea acquired Agios Pharmaceuticals' oncology business
for another $2 billion.

In addition to the external acquisition of oncology business, Svea's R&D investment in the field of internal tumors is also increasing
.
In 2019-2020, Svejas invested 50% of the Group's R&D budget in the field of
oncology.

In addition to the external acquisition of oncology business, Svea's R&D investment in the field of internal tumors is also increasing
.
In 2019-2020, Svejas invested 50% of the Group's R&D budget in the field of
oncology.

As of the end of last year, Svea had 6 marketed products and 14 oncology clinical research and development projects targeting gastrointestinal and other solid tumors, as well as leukemia and lymphoma, in the field of solid tumors and hematological tumors
.

As of the end of last year, Svea had 6 marketed products and 14 oncology clinical research and development projects targeting gastrointestinal and other solid tumors, as well as leukemia and lymphoma, in the field of solid tumors and hematological tumors
.

Currently, Svea's main areas of focus include cardiometabolic diseases, oncology, neuroscience and immune inflammation
.

Currently, Svea's main areas of focus include cardiometabolic diseases, oncology, neuroscience and immune inflammation
.

Svea in China

Sveja in ChinaScuvia in ChinaScuvaSveja in China

Svea entered the Chinese market in 1979 and currently has a production base and R&D center in China, covering 29 provinces and cities and more than
2,000 employees.
Since 2015, China has been the largest contributor to Sveia's global sales performance, and Sveia China has become its largest subsidiary
.

Svea entered the Chinese market in 1979 and currently has a production base and R&D center in China, covering 29 provinces and cities and more than
2,000 employees.
Since 2015, China has been the largest contributor to Sveia's global sales performance, and Sveia China has become its largest subsidiary
.

It is reported that China is not only one of the most important strategic markets in the world, but also the first country
outside of Svea's headquarters in France to have complete early drug development capabilities and commercialization functions.

It is reported that China is not only one of the most important strategic markets in the world, but also the first country
outside of Svea's headquarters in France to have complete early drug development capabilities and commercialization functions.

In December last year, Sveia China's Oncology Division was officially established, making adequate preparations
for the new products that will be approved in a few months.

In December last year, Sveia China's Oncology Division was officially established, making adequate preparations
for the new products that will be approved in a few months.

Then in April this year, Svea pancreatic cancer treatment drug Eanda was officially approved by the State Drug Administration, breaking the domestic situation that no treatment plan for pancreatic cancer had been approved for pancreatic cancer in the past 23 years after gemcitabine was approved in 1999, bringing innovative solutions for pancreatic cancer patients
.

Then in April this year, Svea pancreatic cancer treatment drug Eanda was officially approved by the State Drug Administration, breaking the domestic situation that no treatment plan for pancreatic cancer had been approved for pancreatic cancer in the past 23 years after gemcitabine was approved in 1999, bringing innovative solutions for pancreatic cancer patients
.